Medios AG
Research Medios AG (ILM1.DE) on Bullrun: market cap EUR 264.24M, P/E 22.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerILM1.DE
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryMedical Distribution
- CurrencyEUR
- Market capEUR 264.24M
- P/E22.5
- Financial periodQ2 2026
- RevenueEUR 547.31M
- Net incomeEUR 3.54M
- Free cash flow-EUR 6.81M
- Gross margin9.1%
Valuation Snapshot
latest market cap is EUR 264.24M; P/E is 22.5.
Peer valuation comparison
Latest P/E is 22.52x versus a Healthcare sector median of 24.6x (8.4% below).
Latest P/E is 22.52x versus a Germany median of 15.65x (43.9% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | EUR 264.24M | 22.5 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medios AG's market cap?
Medios AG's market capitalization is EUR 264.24M.
What is Medios AG's P/E ratio?
Medios AG's price-to-earnings (P/E) ratio is 22.5.
What does Medios AG do?
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions.